Aim The only studies on the prognosis of T1 tumours are old and investigate colic and rectal cancers. Very few studies use Kikuchi's classification (of dividing submucosa into three strata) to evaluate the depth of the submucosal invasion. This study aimed to assess the pathological risk factors for lymph node metastasis (LNM), and the pathological and oncological results of patients with early rectal cancer (ERC, pT1 tumour).
Introduction
Early rectal cancer (ERC) is defined as carcinoma that only invades the submucosa. This corresponds to a T1 tumour in the tumour-node-metastasis (TNM) classification [1, 2] and its incidence ranges from 3 to 9% of all resected colorectal cancers [3] [4] [5] . The management of ERC depends on the histopathological classification of the tumour, the depth of submucosal invasion and the risk of lymph node metastasis (LNM). Often, the best plan is made retrospectively once the tumour has been removed and the histopathological stage has been confirmed.
Many studies have focussed on the risk of lymphatic dissemination in ERC, and possible risk factors of LNM have been studied, including the depth of submucosal invasion, tumour location in the rectum, tumour budding, lymphovascular invasion, cribriform-type structural atypia and tumour size [3, [6] [7] [8] [9] . The overall rate of LNM is reported to range from 6 to 29% [10, 11] . The main studies that report LNM rates are listed in Table 1 [3, . The LNM rate increases with the depth of Sm1 n/total n (%) Sm2 n/total n (%) or (%) Sm3 n/total n (%) or (%) Brodsky et al. [12] . 
Sitzler et al. [10] submucosal invasion, from 0 to 18% in Sm1 tumours, from 0 to 25% in Sm2 tumours and from 12 to 38% in Sm3 tumours. Most series are, however, old and include a heterogeneous population of colonic and rectal tumours, frequently of T1 and T2 stages. There is often no mention of the Kikuchi classification [6] . Furthermore, the two most recent studies, including only T1 rectal tumours, show that the LNM rate is above 10%, even for Sm1 tumours. Curative treatment of rectal cancer is based on rectal resection with total mesorectal excision (TME). In the treatment of ERC, this may be overtreatment for patients with a low risk of LNM. Because of the risk of perioperative complications, the possibility of poor bowel function and mortality [34] [35] [36] [37] [38] , some patients are treated with local excision (LE) as the definitive surgical alternative. LE retains anal function and preservation of the organ but is associated with a potential risk of leaving involved lymph nodes behind. LE does indeed have fewer postoperative complications and a lower mortality than TME, but it does not offer oncological results comparable with those observed following TME [39] . The choice of LE for a T1-Sm1 tumour and of TME for a T1-Sm3 tumour is reasonably well established, but there is still controversy regarding the treatment of T1-Sm2 tumours and there are no clear guidelines. The present study aimed to assess the histopathological risk factors for LNM in pT1 rectal cancer and the cancerspecific results after surgery.
Method Study population
From January 2000 to December 2014, all consecutive patients who underwent a surgical resection for primary rectal adenocarcinoma in Saint-Antoine Hospital (Paris, France) were identified from a pathological prospective database. Only patients with a pT1 rectal cancer were included in the study. Patients with synchronous colorectal cancers and those who received neoadjuvant treatment for ypT1 tumour were excluded.
Demographic features (age, gender and body mass index), preoperative clinical features (American Society of Anesthesiologists score and tumour location), surgical features (procedure performed), pathological features (including the pTNM classification, depth of submucosal invasion, the presence of vascular embolism and perineural invasion, margin involvement) and long-term oncological results (death, overall and disease-free survival, locoregional recurrences and distant metastases) were collected retrospectively from a prospectively maintained database. Follow up was assessed using medical files or by telephone interview with the general practitioner or the patient.
Perioperative findings and surgery
Preoperative assessment included digital rectal examination, endorectal ultrasound and/or MRI. Surgery was TME or LE, depending on the preoperative stage.
Mesorectal excision is well described [40, 41] . A laparoscopic approach was used according to the surgeon's practice but this approach is universally advocated. For a tumour in the upper third of the rectum, rectal dissection was carried out 5 cm below the lower border of the tumour with partial mesorectal excision and colorectal anastomosis. For a tumour in the mid or lower rectum, TME dissection was carried out to the pelvic floor and a coloanal anastomosis was performed. For rectal cancers located less than 10 mm from the dentate line, an abdominoperineal excision with a permanent colostomy was performed. All extraperitoneal anastomoses were diverted by a defunctioning ileostomy.
LE was carried out in patients diagnosed with a T1 rectal cancer on preoperative endorectal ultrasound. LE was performed either through a transanal approach for very low rectal tumours or by transanal endoscopic microsurgery (TEM) for higher lesions. If adverse histopathological findings were found, LE was followed by radical surgery.
Histopathological examination
Histopathological examination of the resected specimen was performed according to a standardized protocol [42] following the pTNM classification [2] . The depth of invasion into the submucosa was defined according to the Kikuchi classification (Sm1, Sm2 and Sm3) [6] . The circumferential resection margin was defined as positive if the primary tumour or an involved lymph node were found to be ≤ 1 mm from the margin of the specimen. The distal margin was considered R1 when invaded by tumour cells. When available, histopathological slides were reviewed by a specialist intestinal histopathologist.
Tumour budding was defined as the presence of isolated single cancer cells or a small cluster composed of fewer than five cancer cells scattered in the stroma at the advancing edge of the invasive tumour [43] . To realize a immuhistochemical detection, we select the block containing the highest degree of budding according to standard review of diagnostic slides, tumour buds were detected using a pan-cytokeratin AE1/AE3 stain (Dako, Les Ullis Cedex, France) (mouse monoclonal; 1:200 dilution; enzyme pretreatment 5 min; DAB chromogen) [44] . More than 10 buds per high-power field (940 magnification) were regarded as positive.
Follow up
Adjuvant chemotherapy was discussed during a multidisciplinary meeting for patients who had lymph node invasion on histopathological examination. All patients were followed every 3 months during the first 2 years after surgery, every 6 months during the next 3 years and annually thereafter. During follow up, the patients underwent clinical examination, a thoraco-abdominopelvic CT scan and blood was taken to measure the levels of carcinoembryonic antigen and carbohydrate antigen 19.9. Colonoscopy was performed 1 year after surgery, then every 3 years thereafter.
Locoregional recurrence was defined as recurrent disease within the pelvis, including recurrence at the site of the anastomosis and of the perineal wound. In patients with suspected locoregional recurrence, a pelvic MRI was performed and a pathological diagnosis of cancer was always confirmed by biopsy. Metastatic recurrence, diagnosed mainly by imaging, included liver metastasis, metastasis at other extra-abdominal sites and nodal metastasis beyond the regional nodes.
Statistical analysis
Data are presented as mean AE SD for quantitative data and as number (percentage) for categorical variables. Comparisons were carried out using the Student's t-test and Pearson's chi-square test or Fisher's exact tests, as appropriate.
Survival was estimated using the Kaplan-Meier method, and the log-rank test was used to compare survival curves. Overall survival was defined as the interval from the date of surgery to the date of death or the date of last follow up for patients still alive. All causes of death, including postoperative deaths, were considered for overall estimation of survival. All tests were two sided with a level of significance set at P < 0.05. All analyses were performed using JMP9 (SAS Institute Inc., Cary, North Carolina, USA).
This study was conducted according to the ethical standards of the Committee on Human Experimentation of our institution and was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [45] .
Results

Study population
From January 2000 to December 2014, 121 consecutive patients with pT1 rectal cancer on histopathological examination of the excised specimen received surgery at Hôpital Saint-Antoine, Paris. Of these patients, 10 had a synchronous colorectal cancer. Twenty patients received neoadjuvant treatment and were also excluded from the analysis. The remaining 91 patients with early rectal cancer were included in the study (Fig. 1) . The baseline characteristics of the population are given in Table 2 .
Fifty-one (56%) patients were treated by a primary TME, 18 (20%) underwent LE alone and 22 (24%) underwent LE followed by a secondary TME. Secondary surgery was performed in the following groups: in two Sm1 patients (n = 2/17; 12%) owing to an R1 resection; in 12 Sm2 patients (n = 12/18; 67%); in six Sm3 patients (n = 6/8; 75%); and for the two patients with unknown Sm status. The reasons for choosing not to perform a secondary TME in Sm2 and Sm3 patients were age over 75 years (n = 4), associated severe comorbidity (n = 7) and the absence of poor histopathological criteria in one Sm2 patient.
Histopathological features
The histopathological features are shown in Table 2 . Macroscopic analysis showed piecemeal resection in nine (10%) patients. This occurred only after LE: in three patients after endoscopic resection (n = 3/4; 75%), in five after transanal excision (n = 5/29; 17%) and in one after TEM (n = 1/7; 14%).
The proportions of Kikuchi stages Sm1, Sm2 and Sm3 were 34% (31 patients), 32% (29 patients) and 32% (29 patients). The depth of submucosal invasion could not be classified in two (2%) patients. An R0 resection was achieved in 81 (89%) patients and an R1 resection was achieved in the remaining 10 (11%; including two patients after LE and eight after TME). Five patients treated with a TME had circumferential involvement from a mesorectal involved lymph node, two patients had distal margin involvement and one had involvement of both circumferential and distal margins.
Lymph node involvement
Of the 73 patients with TME, lymph node status was known in 70. The median (range) number of lymph nodes examined was 22 (8-167) per specimen. Sixteen (23%) patients had LNM (Table 3 ). Patients with LNM had an average of 3 AE 2 (range: 1-9) involved nodes. The node-positive rate was 15%, 14% and 30% in patients with Kikuchi stages Sm1, Sm2 and Sm3, respectively (P = 0.326).
Histomorphological parameters were evaluated statistically to determine their correlation with LNM (Table 4 ). Univariate analysis showed that piecemeal resection (P = 0.001), lymphovascular invasion (P = 0.001) and high tumour budding (P = 0.043) were associated with a significantly increased risk of LNM. The depth of submucosal invasion was not significantly associated with increased LNM. In multivariate logistic regression (Table 4) , only lymphovascular invasion (OR = 6.3; 95% CI: 1.2-50.8; P = 0.027) and high tumour budding (OR = 7.6; 95% CI: 1.1-152.2; P = 0.037) were independent risk factors for LNM. Considering these two risk factors identified in multivariate analysis, we evaluated the risk of LNM according to the presence or absence of these risk factors in the same patient (Table 5 ). The risk was 0% (n = 0/18) when there was no risk factor, regardless of the depth of submucosal invasion, and 36% (n = 14/39) when one or two risk factors were present.
Survival analysis
After a mean follow up of 56 AE 46 (range: 0-178) months, 10 (11%) patients had died, including four (4%) from cancer-related death. Nine (10%) patients had developed recurrence: six with distant metastasis; two with local recurrence; and one with both. The 5-year overall survival, specific survival and disease-free survival were 82%, 93% and 75%, respectively. There was no statistical difference in 5-year disease-free survival according to the surgical management (P = 0.87) or the depth of submucosal invasion (P = 0.168) (Fig. 2) .
Discussion
In the present study, 91 patients with pT1 rectal cancers underwent surgery. After TME (n = 73), LNM were detected in 16 (23%). The rate of lymph node involvement was 15%, 14% and 30%, respectively, in patients with Sm1, Sm2 and Sm3 tumours. In univariate analysis, lymphovascular invasion, piecemeal resection and a high degree of tumour budding were factors predictive of LNM. In multivariate analysis, lymphovascular invasion and high tumour budding were both independent risk factors. After a mean follow up of 56 months, 10 (11%) patients had died and nine (10%) had recurrence, including three with local recurrence. The 5-year overall survival, specific survival and disease-free survival were 82%, 93% and 75%, respectively. Secondary TME (n = 18) Secondary TME EARLY RECTAL CANCER Figure 1 Flow diagram of 121 patients with pT1 rectal cancer. TME, total mesorectal excision.
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In the literature, many studies have focussed on the prognosis of small colorectal cancers, especially pT1 tumours. These series include 5938 patients (Table 1) with an overall rate of LNM of 12%, but over half of these had colonic cancer in which the LNM rate seems to be higher than in the rectum [6, 8, 46] . Our literature review is in agreement with the findings of this report, with LNM rates of 13% in rectal cancer and 10% in colonic cancer (P = 0.009). ERC is different from early colonic cancer and LNM appear to be more common in such tumours. These results highlight the need for specific studies on ERC. Consequently, we present one of the largest series of specifically rectal pT1 tumours.
In our series, three of the 20 patients who underwent TME for a pT1-Sm1 tumour had LNM, amounting to a risk of 15%. These had unfavourable histopathological features, such as lymphovascular invasion. This result contradicts the initial rates published by Kikuchi, who found no case of LNM among their 35 patients with pT1-Sm1 rectal cancer [6] . Nevertheless, this publication is old, and two more recent studies, including 55 and 68 patients with ERC, have found an LNM rate of above 10% for Sm1 tumours, similarly to this study [24, 32] . Despite the small sample size, these figures nevertheless indicate that the risk of lymph node involvement in Sm1 cancer may have been underestimated. For Sm2 tumours, no clear guidelines exist and the different therapeutic options are often discussed on a case-by-case basis. The 14% rate of LNM in the present study is consistent with the published data [6, 24, 32] . At least one-third of our patients with an Sm3 tumour had LNM. After LE, only two patients with Sm3 cancer did not have a subsequent TME, largely owing to comorbidity and age. One of these patients presented with local recurrence at 6 months. TME is the gold-standard treatment for an Sm3 tumour and LE should be an exception that is reserved for older patients and/or those with serious comorbidity.
The results of the present study, and of others, therefore indicate that the depth of submucosal invasion is probably not a relevant factor to define the risk of LNM and determine the surgical management. Indeed, many studies have identified pathological criteria that are related to LNM and permit division into 'high' or 'low' risk. TME after LE should be discussed when the relevant pathological features are present. For Sm3 tumours in which the risk is 30%, TME must be the basic treatment. In the case of Sm2 and Sm1 tumours, the rate of LNM is 0% when there are no risk factors and 36% when there is at least one. Consequently, the presence of a single, poor, histopathological factor on examination of an LE specimen should lead immediately to discussion of TME. LE should be reserved for Values are given as n (%) or as mean AE SD. ASA, American Society of Anesthesiology; CAA, coloanal anastomosis; CRA, colorectal anastomosis; TEM, transanal endoscopic microsurgery; TME, total mesorectal excision. patients with an Sm1 or Sm2 tumour when there is no lymphovascular invasion, tumour budding, piecemeal resection and tumour at the margin of the specimen (R1 resection). There has been much interest in ERC and its risk of LNM, but it is difficult to identify predictors of LNM with confidence because of the heterogeneity of patients. In many studies, the number of patients is small and some series include either colonic or rectal cancers, or both, and many combine pT1 and pT2 tumours. Subdivision of submucosal penetration may be irrelevant in many studies because location of tumour in the rectum [6, 8, 46] and pT2 stage [10, 29, 31] have been Values are given as n/total n (%).
identified as factors undoubtedly associated with lymph node involvement. Only one study looked specifically at risk factors for LNM in early rectal cancer and none was demonstrated [32] . Lymphovascular invasion has been consistently reported in the literature to have high risk of LNM in pT1 carcinoma [8, 9, 12, 14, 24] and this was confirmed to be statistically significant in the present study in which, furthermore, tumours with lymphovascular invasion had deeper submucosal invasion than did those without (data not shown). This could explain why, in other series, the depth of submucosal invasion and not lymphovascular invasion seemed to increase the risk of LNM. Another risk factor identified in the present study is piecemeal resection where there was a large difference in LNM for tumours removed piecemeal (75%) or whole (16%). In the nine patients treated with piecemeal resection, this had been carried out after LE and eight of these procedures had been performed before 2011, mostly by endoscopic removal or transanal excision. All of these patients, except one 80-year-old woman with cardiac comorbidity, had a subsequent TME at a median of 47 days after the LE . Of these, six had LNM and two did not. One patient died of metastatic disease in each of these groups. Piecemeal resection could cause release of cancer cells into the circulation with the metastatic potential favoured by the local trauma of the surgery. In the case of LE, complete resection is a major criterion of quality and, given the availability of new surgical technologies, piecemeal excision should not be performed. For this reason, whenever possible, TEM should be performed instead of conventional transanal surgery. Fragmentation of the tumour is significantly less likely with TEM than with conventional transanal excision [47] [48] [49] . Recently, Clancy et al. [50] published a meta-analysis of six comparative studies, including 927 patients. This confirmed the superiority of TEM over transanal excision in achieving complete monobloc resection (OR = 0.096, P < 0.001) and R0 resection (OR = 5.281, P < 0.001) and in minimizing local recurrence (OR = 0.248, P < 0.001).
Tumour budding is correlated with the risk of lymph node invasion and survival [43, 51] . In a series of 56 patients with pT1 CRC, Kazama et al. [20] reported an LNM rate of 38% in the presence of budding and an LNM rate of zero when budding was absent (P = 0.004). Similarly, when focussing specifically on ERC, Masaki et al. [52] showed that budding was not only a risk factor for LNM, but was also a risk factor for local recurrence after LE, only for ERC (P = 0.048). Therefore, tumour budding would be important in the evaluation and surgical management of pT1 carcinoma, but the lack of standardized methods for its identification has been responsible for the low use of this marker. Tumour budding should be assessed after staining with a pan-cytokeratin antibody, as in the present study; this greatly improves the identification of buds [16] . Using this method, our results are concordant with those reported by Ueno et al. [16] . One of the weaknesses of our study is the lack of multivariate analysis, but the small sizes of the groups do not allow a valid analysis.
The current study used three surgical strategies for treating ERC: primary TME; LE alone; and LE followed by salvage TME. No significant difference was found between them in the risk of regional LNM or survival. In the current era of 'organ preservation', LE is attractive as it avoids the morbidity of TME and preserves satisfactory bowel function. Two meta-analyses have shown superiority of LE, compared with TME, in various end-points, including postoperative morbidity (8% vs 47%, P = 0.01), major postoperative morbidity (4% vs 16%, P < 0.001) and mortality (0.4% vs 2%, P = 0.005) [39, 53] ; on the other hand, LE offers poorer oncological results owing to the risk of involved nodes in the mesorectum that are not removed by the surgery. This results in lower overall and cancer-specific survival (P > 0.001), and higher local recurrence rates, than TME. The lack of a significant difference in our study may, first, be related to the small size of the groups, despite a 14-year study period, and, second, to the rigorous selection of patients for LE.
In conclusion, we highlight the specific natural history of ERC with a higher rate of regional lymph node involvement than in early colon cancer. In contrast to the findings of Kikuchi et al. [6] , the depth of submucosal invasion does not predict the presence of LNM in ERC. Other histopathological factors, such as lymphovascular invasion and budding, are the best histopathological indicators of regional lymphadenopathy.
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